Clinical Trial Update: A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis [Phase 3]

View source ↗

Summary

Phase 3b trial evaluating a specified dosing algorithm for erythropoietin drugs in chronic kidney disease patients on hemodialysis has completed and posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)
• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: Pfizer | Conditions: Chronic Kidney Disease (CKD) | Phase 3 | Status: COMPLETED | Results posted: 2018-06-13